- Home
- GRNT vs AUPH Comparison
GRNT vs AUPH Comparison
Compare GRNT & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRNT
- AUPH
- Stock Information
- Founded
- GRNT 2013
- AUPH 1993
- Country
- GRNT United States
- AUPH Canada
- Employees
- GRNT N/A
- AUPH N/A
- Industry
- GRNT Blank Checks
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- GRNT Finance
- AUPH Health Care
- Exchange
- GRNT Nasdaq
- AUPH Nasdaq
- Market Cap
- GRNT 752.6M
- AUPH 1.1B
- IPO Year
- GRNT N/A
- AUPH 1999
- Fundamental
- Price
- GRNT $5.76
- AUPH $8.86
- Analyst Decision
- GRNT Buy
- AUPH Strong Buy
- Analyst Count
- GRNT 2
- AUPH 2
- Target Price
- GRNT $7.50
- AUPH $11.50
- AVG Volume (30 Days)
- GRNT 997.5K
- AUPH 1.9M
- Earning Date
- GRNT 08-07-2025
- AUPH 07-31-2025
- Dividend Yield
- GRNT 7.61%
- AUPH N/A
- EPS Growth
- GRNT N/A
- AUPH N/A
- EPS
- GRNT 0.09
- AUPH 0.27
- Revenue
- GRNT $390,665,000.00
- AUPH $247,295,000.00
- Revenue This Year
- GRNT $30.32
- AUPH $12.15
- Revenue Next Year
- GRNT $7.79
- AUPH $18.31
- P/E Ratio
- GRNT $64.14
- AUPH $33.04
- Revenue Growth
- GRNT 6.26
- AUPH 29.20
- 52 Week Low
- GRNT $4.52
- AUPH $5.20
- 52 Week High
- GRNT $7.10
- AUPH $10.67
- Technical
- Relative Strength Index (RSI)
- GRNT 39.46
- AUPH 64.10
- Support Level
- GRNT $5.76
- AUPH $7.36
- Resistance Level
- GRNT $6.72
- AUPH $9.10
- Average True Range (ATR)
- GRNT 0.20
- AUPH 0.44
- MACD
- GRNT -0.10
- AUPH 0.10
- Stochastic Oscillator
- GRNT 0.52
- AUPH 89.53
About GRNT Granite Ridge Resources Inc.
Granite Ridge Resources Inc is a scaled, non-operated oil and gas exploration and production company. It invests in a diversified portfolio of production and top-tier acreage across the Permian and other prolific U.S. basins in partnership with operators. It generates maximum revenue from Oil.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.